Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% weight on average in a year-long ...

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...

STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...